$HIMS

$HIMS · Asymmetric Investing by Travis Hoium · 2026-11-10

AI 摘要 · Asymmetric Investing by Travis Hoium

HIMS 在令人失望的季度后下跌 18%:订阅用户环比减少约 10 万,受品牌 GLP-1 产品结构影响,毛利率从 83% 降至 57%,第四季度营收指引小幅下滑,全年调整后 EBIT 指引被下调。说话者并未卖出,仍认为 HIMS 是值得持有 5-10 年的优秀公司,依据是其更高定价的订阅、TRT 与肽类策略以及类似 Costco 的健康订阅模式,管理层把希望押在 2027 年第一季度;短期订阅用户增长与竞争仍存疑问,下一季度指引很重要。

看涨他说的是几年内
《Hims & Hers Collapses 30% In a Week》
Asymmetric Investing by Travis Hoium发布 2026-11-10 · 38 段内容

播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策

00:00/ —打开原视频

逐段跳播

38 段内容
0:0011:05

他和他妻子的公司周一公布了财报,周二盘后交易中,两人的股票下跌了18%。投资者不喜欢他们在财报中听到的内容。从很多方面来看,这份财报确实令人失望。订阅用户数环比下降。毛利率继续承压。

而且管理层表示,他们实际上并没有花那么多钱去获取那些新客户。这就是增长真正放缓的原因。

Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.

In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.

他们也没有谈到2030年的业绩指引,而这是他们过去一直都会做的事。但长期来看,这实际上可能是合理的。要弄清楚管理层在这里做的事情是否正确,还需要一段时间。

They also did not talk about their 2030 guidance, something that they've done consistently in the past. But long-term, this may actually make sense. It's going to take a while to figure out if management is doing the right things here.

他们请来了Andrew Huberman加入董事会,他也将担任公司的顾问。所以,他大概率会大力推动肽类业务。

They brought Andrew Huberman on to the be on the board of directors, also going to be an adviser to the company. So, he's probably going to be a big push into peptides.

让我们直接来看看昨天进入当天时我投资组合中排名第一的持仓。那就是Hims and Hers。现在它降到了第四位,因为Zeta Global大幅上涨。

And let's dig right into the position that was number one in my portfolio going into the day yesterday. That's Hims and Hers. Now down to number four after a pretty big jump from Zeta Global.

今天晚些时候会在频道上聊它们。Hims and Hers,就像我说的,股价下跌了18%,而过去一个月股价下跌了约40%。所以,Hims and Hers最近在股市上的表现真的非常非常糟糕。

Cover them on the channel later on today. Hims and Hers, like I said, shares down 18% and over the past month, shares are down about 40%. So really, really bad performance on the stock market recently for him and hers.

我们先从营收说起,因为营收同比增长了49%。这通常会是件非常好的事,但其中很大一部分营收来自他们收购的Eucalyptus。所以这就是本季度营收增长成这样的原因。

We're going to start with revenue because revenue was up 49% from a year ago. That would normally be a really good thing, but a lot of this revenue is coming from their eucalyptus acquisition.

So that's the reason revenue was up like it was in the quarter.

管理层还指引第四季度营收会小幅下降。毛利率,从百分比来看,毛利率大幅下降。过去曾在83%这个区间。那时他们卖了很多仿制药,很多复方产品。现在降到了57%。

Management also guid guided for reven revenue to be down a little bit in the fourth quarter. Gross margin, gross profit margin from a percentage standpoint is down sharply. Used to be in this 83% range.

That was when they were selling a lot of generic products, a lot of compounded products. Now that's down to 57%.

原因是他们现在卖更多品牌GLP1。所以他们与Novo Nordisk达成了协议。他们最近还与Eli Lilly达成了协议。我们将会看到利润率方面承压。

The reason is they're selling a lot more branded GLP1s. So they've made deals with Novo Nordisk. They've made made a deal recently with Eli Liy. We're going to see pressure on the margin side.

不过好消息是,别忘了这一点,毛利金额仍在继续上升。所以,尽管平台上订阅用户数环比实际上是下降的,Hims and Hers赚到的毛利实际金额仍在继续上升。

The good news though, and don't forget this, is that the gross margin dollars continue to go up. So, the amount of actual dollars in gross profit that Hims and Hers is making continues to go up despite the fact that sequentially the number of subscribers on the platform was actually down.

这是营业利润。所以,过去两个季度营业利润率约为负13%。本季度略有好转。这背后有多个不同因素。把一些一次性成本调整出去后,他们确实实现了正的调整后EBIT。他们因为招聘了大量人员而产生了大量股权激励费用。

所以这在一定程度上造成了这些亏损,但绝对值得关注。

This is the operating profit. So, the operating operating margin was negative about 13% over the past two quarters. Got a little bit better this quarter. There are a number of different factors for that.

They did have positive adjusted EBIT. once you adjust some of the one-time costs out. They've had a lot of stockbased compensation for hiring a lot of people. So, that's driving some of these losses here, but definitely something to keep an eye on.

现在,我并不太担心营业利润。我其实希望它略微为正。我不喜欢它是负的,但话说回来,这也是投资者担心的另一件事。现在,最大的负面因素,如果你要从这个季度挑出任何负面因素,那一定是这个数字。

这是Hims and Hers的订阅用户数。第三季度比第二季度减少了约10万订阅用户。所以,每个季度付费给Hims and Hers的人数实际上在下降。

Now, I'm not super worried about operating profit. I actually want this to be slightly positive. Don't like that it's negative, but again, another thing that investors are worried about.

Now, the biggest negative, if you're going to take any negative from the quarter, it has to be this number right here. This is the number of subscribers for him and hers. and it was down about a 100,000 subscribers in the third quarter versus the second quarter.

So the number of people paying him and hers each quarter is actually going down.

这里的背景是这条蓝线,即每位平均订阅用户的月度营收。所以每位订阅用户的月度营收继续上升。原因是什么?原因是Hims and Hers已经不再依赖他们赖以成长起来的一些低价产品,比如ED、脱发,这些可能每月20美元、30美元的产品,而是转向更多像GLP1这样的高价产品,这类产品的起点是每月300美元。

Now the context for that is the blue line here which is the monthly revenue per average subscriber. So the monthly revenue per subscriber continues to go up. What is the reason for this?

The reason is that Hims and Hers has moved away from some of the lowcost products that they've really grown up on, ED, hair loss, things that maybe are $20 a month, $30 a month, and they moved into more of these higher price items like GLP1s where you're talking about a starting point of $300 per month.

他们做的另一件事是,即便是那些产品也转向了更高的价格点。所以,如果你回顾他们大量销售复方GLP1的时候,每月150美元就能买到。现在,每月150美元是GLP1本身、处方本身的起点价。

除此之外,你还要支付会员费。所以这里面有两部分。这就是人们花更多钱订阅Hims and Hers的原因。

The other thing that they've done is moved to higher price point for even those products. So, if you look back to when they were selling a lot of compounded GLP ones, you could get those for $150 per month.

Now, it's $150 per month from a starting point for the GLP1 itself, for the prescription itself. And on top of that, you pay for a membership. So, there's two pieces of this. This is the reason that people are spending more on the subscriptions that they have to hims and hers.

所以,公司显然在做的是,从那些较低成本的订阅转向更多这些较高成本的订阅。代价就是平台上订阅的人变少了。

So, what the company is clearly doing is moving away from those lower cost subscriptions and more towards these higher cost subscriptions. The trade-off is you just simply have less people subscribed to the platform.

管理层还表示,他们最近在销售和市场营销上的支出减少了,随着他们为今年晚些时候以及随后进入2027年即将推出的一些新产品做准备,他们削减了其中一部分支出。所以,你实际上可以在左边紫色的数字里看到这一点。

销售、一般及行政费用。这项费用环比下降了近2000万美元。所以,我们在数字中看到了这一点。

Management also said that they've been spending less on sales and marketing recently, pulling back on some of that as they prepare for some of their new products that are going to be coming out later this year and then into 2027.

So, you actually see that in the numbers right here on the left in purple. Selling general and administrative expenses. That was down nearly $20 million quarter over quarter. So, we're seeing that in the numbers.

他们在研发上也投入了多得多的资金。也就是在打造他们的AI能力之类的东西上。管理层说这些东西能让平台更有吸引力,但我们并没有真正看到人们因此更多地订阅这个平台。

They're also spending a lot more money on R&D. So, building out their AI capabilities and things like that. This is stuff that management said is more engaging on the platform, but we're not quite seeing that in people actually subscribing more to the platform.

所以,这个故事里存在一种拉扯,就是Hims and Hers那边的情况。公司并没有以你可能希望的那种方式增长。

So, there's kind of a push and pull here in the story that what's going on with him and hers. The company's not growing the way that you would maybe like.

管理层说:“你知道吗?GLP1领域的竞争已经变得非常激烈了。我们可能想从一些即将推出的新产品上省下一些钱,比如TRT、比如肽类,我们想在2027年初大干一场,因为那时候人们才真正准备好减重、为2027年定下目标。

那时候我们才会看到更大的机会。”这就是他们在财报电话会议上讲的那套说法。

Management said, "You know what? It's gotten really competitive out there in the GLP1 space. We want maybe want to save some of our money from some of these new products that are coming out like TRT, like peptides, and we want to go big in the early part of 2027 when that's when people are really primed to be losing weight, set their goals for 2027.

That's when we see a bigger opportunity." That's the story that they were telling on the conference call.

这就是TRT,他们几周前刚刚宣布的。所以,这已经来到了Hims and Hers。我们已经看到了一些相关的广告。所以,我们开始通过橄榄球看到这一点,这是他们说过会加大广告投放的领域。

预计可能会在2027年初的NFL季后赛期间看到。

This is TRT, which they just announced a couple of weeks ago. So, this has come to him and hers. We've seen some advertising for this already. So, we're starting to see that with football, something that they said they are going to advertise more.

Expect to see that maybe in the NFL playoffs early in 2027.

再说一次,这会与人们所说的“也许我想在假期之后减掉一点体重”的时间点相吻合。他们在寻找这类解决方案。Hims and Hers已经说了:“嘿,我们想成为人们在那段时间里的解决方案。”

Again, this is going to line up with when people are saying, you know, maybe I want to lose lose a little bit of weight after the holidays. They're looking for those kind of solutions.

Himson and Hers has said, "Hey, we want to be the solution for people at that period of time."

这里的价格点是,你会得到一个50美元的会员资格。再说一次,这大致就是Hims and Hers正在转向的趋势,也就是不同的会员类型。减重会员150美元,TRT会员50美元,然后处方药从每月50美元起,最高到每月180美元。

The price point here, you're going to get a $50 membership. Again, this is kind of the trend that Hims and Hers is moving toward is different memberships. $150 for weight loss membership, $50 for a TRT membership, and then prescriptions start at $50 a month, go all the way up to $180 a month.

2027年更大的事情,而且他们实际上说这个会在本月晚些时候推出,就是肽类。所以,肽类将会登陆这个平台。并不是所有肽类都会提供。特别是BBC57一开始不会提供,至少这是他们目前的计划。

The bigger thing in 2027, and they actually said this is going to be launching later this month, is peptides. So, peptides are going to be coming to the platform. Not all of them are going to be be available.

In particular, BBC57 is not going to be be available initially, at least that's their current plan.

但Hims and Hers的一大差异化优势在于,他们将在内部自行生产其中很大一部分。他们在财报电话会议上这么说了。所以本月晚些时候,Samarellan、gluion和NAD plus将在平台上提供。

BBC157和TB500会稍晚一些推出。他们还将在Menllo Park生产原料API。也就是在他们自己的内部设施里,所以这些将是100%在美国生产。

But the big differentiator for him and hers is that they are going to be making a lot of this in-house. So they said that on the conference call. So later this month, Samarellan, gluion, and NAD plus are going to be a available on the platform.

BBC157 and TB500 are going to be coming a little bit later. They're also going to be making the raw APIs in Menllo Park. So in their internal facility, so these are going to be 100% produced in the US.

我认为,就肽类业务而言,这最终会成为Hims and Hers一个相当大的差异化优势。但这会有多大?它在2026年以及随后进入2027年会以多快的速度扩张?这是我们现在并不真正知道的。

I think that's going to ultimately be a pretty big differentiator for him and hers when it comes to the peptides business. But how big is that going to be? How fast is it going to scale both in 2026 and then into 2027?

That's something that we don't really know right now.

所以管理层说的是,嘿,我们在第三季度和第四季度初收手了本可以去收购的增长,因为我们认为,在2027年初去获取那些将成为长期高价值客户的客户,存在更大的机会。而从处方角度看,那里的驱动力将是TRT和肽类。

So what management is saying is, hey, we pulled back on growth that we could have gone out and acquired in the third quarter and early into the fourth quarter because we think that there's bigger opportunities to acquire those customers that are going to be long-term big values in early 2027.

And the driver there from a prescription standpoint is going to be TRTs and peptides.

为此,Andrew Huberman博士也宣布他将加入董事会,并将担任公司的顾问。所以再说一次,你看Hims and Hers是看短期还是看长期?短期来看,公司肯定面临压力。我不喜欢他们没有在增加订阅用户数量这一点。

To that end, Dr. Andrew Huberman also announced that he is going to be joining the board of directors and is going to be an adviser for the company. So again, are you looking at him and hers short-term or are you looking at it long term?

Short-term, there's definitely pressures on the company. I don't like that they aren't growing the number of subscribers.

这里看一下他们对2026年第四季度的营收指引。你可以看到,这很可能比第三季度略有下降。他们调整后的EBITDO利润率并不算太亮眼,为8%到10%。而全年来看,他们实际上下调了调整后EBIT的指引。

Here's a look at their revenue guidance for the fourth quarter of 2026. You can see that that's likely to be down slightly from the third quarter. Their adjusted EBITDO margin not all that impressive at 8 to 10%. and for the full year they actually reduced their adjusted EBIT dot guidance.

所以短期内有很多问题,这个策略是否奏效,但我一直回过头来想的是,我认为Hims and Hers对这个行业长期走向的看法是对的。

So there's a lot of questions short-term is is this strategy working but what I continue to go back to is I think him and hers has the right view of where this industry is going long term.

所以他们在财报电话会议上谈了很多关于要成为人们数据最终汇聚的地方。这包括实验室数据,也包括你每天佩戴的可穿戴设备。有人问到了可穿戴设备的问题,管理层实际上说:“嘿,无论你在哪里佩戴可穿戴设备,我们都希望把那些数据放到Hims and Hers上,但他们最终也会作为订阅的一部分提供那些可穿戴设备。”

So they talked a lot on the conference call about being the place where people's data ends up. So this is labs this is the wearables that you have every day. There was a question about wearables and management effectively said, "Hey, you know, wherever you have a wearable, we want to have that data on him and hers, but they're also going to be providing those wearables eventually as part of subscriptions."

我认为这就是这项业务最终要走向的方向,这会是一门订阅业务,一门订阅健康业务。然后你实际拿到的处方以及其他你付费的东西,利润率会相对较低。这会有点像Costco的模式,会员资格本身才是Costco赚钱的地方,其他一切实际上都是按成本价出售的。

I think that's where the business is ultimately headed is this is going to be a subscription business, a subscription health business. And then the actual prescriptions that you get and other things that you're paying for are going to be relatively low margin.

It's going to be a little bit like a Costco model where the membership itself is where Costco makes the profit. everything else is effectively sold at cost.

这最终可能真的具有颠覆性,因为一旦你开始打造一个包含多个部分、你能从多个部分获得价值的订阅,竞争对手就不可能与之竞争。我认为这是一个合理的长期策略,但这不会帮助第三季度、第四季度的数字。这需要时间才能见效。

That could ultimately be really disruptive because it's impossible for competitors to compete with that once you start to build out a subscription that has multiple pieces to it where you're getting value from multiple pieces.

I think that's a reasonable long-term strategy, but that's not going to help the numbers in the third quarter, in the fourth quarter. Something that's going to take time to play out.

他们还在为未来下大注,押在一些即将推出的新产品上,特别是肽类,而这对公司来说可能风险很大。

They're also making a big bet on the future on some of these new products that are coming, in particular, peptides, and that could be really risky for the company.

但我想回到他们财报信开头的地方。我还想指出,他们这次没有做财报演示。过去好几个季度,他们的演示一直相当一致。我甚至想不起来有哪个季度他们没做那种类似的演示。而本季度他们没有做。

这对我来说又是一个警示信号。当管理层开始展示不同的东西时,就是在告诉你,故事正在发生变化。

But I want to go back to where they started the earnings letter. And I also want to note that they did not have an earnings presentation. So they've done presentations that have been pretty consistent over the past number of quarters.

I can't even go back to when they didn't do that similar presentation. They did not have that in this quarter. That was another sort of red flag for me. When management starts to present different things is telling you that the story is changing.

但我确实喜欢这一句。在医疗健康领域,谁掌握了客户关系,谁就赢了。而这正是我们通过 Hims and Hers 在打造的东西。归根结底,这关乎人们能否从医生和处方中获得真正的选择和真正的价值。

我认为 Hims and Hers 正在打造的就是这样一种平台,但路上总会有波折。这绝对是其中一次波折。

But I do like this line right here. In healthcare, whoever owns the customer relationship wins. And that's exactly what we're building with Hims and Hers. And this comes down to people having real choice and real value in what they're getting from their doctor and from their prescriptions.

I think that's the kind of platform that Hims and Hers is building, but these are there are bumps along the road. This is definitely one of those bumps.

我不会卖出我在 Hims and Hers 的股票,但这是一个会让你产生疑问的季度:这个领域会不会变得竞争极其激烈?来自 Row、来自 Amazon、来自各种其他小玩家的竞争,会不会大到难以应对,以至于长期无法维持一个规模大且盈利的业务?

I'm not selling my shares in Hims and Hers, but this is one of those quarters that kind of makes you question, is this going to be a hyper competitive space? Is the competition that we get from Row, from Amazon, from all kinds of other small players, is that going to be too much to handle to have a big profitable business long term?

管理层必须在接下来几个季度里回答这些问题。他们明确表示的是,他们把大量希望押在了 2027 年第一季度上。所以,我们看看他们在下一次电话会议上会怎么说。到那时,我们就会知道肽类产品在定价和销量两方面是什么样子。他们也会开始知道这些数字大概会是什么样。

Management has to answer those questions over the next handful of quarters. What they're clearly stating is that they're putting a lot of eggs in the Q1 2027 basket. So, we'll see what they say on the next conference call.

By then, we're by then we're going to know what peptides look like from both a pricing standpoint and a volume standpoint. They're going to know what those numbers start to look like.

所以实际上,下个季度的指引会非常非常重要,因为它会告诉你,当他们重新回到获客阶段时,能否以盈利的方式做到这一点,并让整个业务实现盈利增长。

So actually the guidance next quarter is going to be really really important because it's going to tell you when they get back into this customer acquisition zone are they going to be able to do that profitably and grow profitably as a business.

Hims and Hers 有很多问题。我认为,如果你有 5 到 10 年的长期视角,这仍然是一家值得持有的好公司。但本季度确实有一些让人不喜欢它的理由。

Lots of questions for him and hers. I think you look 5 10 years out if you have that long-term horizon. This is still a great company to own. But there are reasons not to like this current quarter.

观察点

下一季度关于盈利性获客与增长的指引
恢复以盈利性增长为前提的获客
下一季度下一次财报电话会/指引
支持长期持有的论点

这个频道对 $HIMS 的历次判断

Asymmetric Investing by Travis Hoium 在这只股票上共 5 条判断,这里只列相邻的几条。

跨洋听风